← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $619B	4,094	-67	-2%	$268B
2	2 AbbVie ABBV $509B	3,789	-39	-1%	$239B
3	3 Merck MRK $369B	3,335	-122	-4%	$156B
4	4 Amgen AMGN $238B	2,858	-77	-3%	$121B
5	5 Pfizer PFE $169B	2,816	-123	-4%	$90.5B
6	6 Bristol-Myers Squibb BMY $125B	2,300	-187	-8%	$76.1B
7	7 Gilead Sciences GILD $197B	2,026	+7	+0.3%	$119B
8	8 Novartis NVS $288B	1,386	+27	+2%	$16.2B
9	9 AstraZeneca AZN $261B	1,224	-29	-2%	$34.7B
10	10 Regeneron Pharmaceuticals REGN $82.7B	1,203	-90	-7%	$46.9B
11	11 GSK GSK $99.1B	892	+32	+4%	$14.5B
12	12 Incyte INCY $23B	659	+29	+5%	$13.4B
13	13 Natera NTRA $57.8B	647	+48	+8%	$22.1B
14	14 Exelixis EXEL $15.5B	635	+76	+14%	$11.2B
15	15 DELISTED Exact Sciences EXAS	559	+1	+0.2%	$9.49B
16	16 Halozyme HALO $13.8B	551	+1	+0.2%	$6.05B
17	17 Jazz Pharmaceuticals JAZZ $14B	502	-49	-9%	$6.57B
18	18 Lantheus LNTH $6.53B	476	-50	-10%	$6.63B
19	19 Tempus AI TEM $12.6B	369	+82	+29%	$5.24B
20	20 Guardant Health GH $22.2B	365	+23	+7%	$6.47B
21	21 DELISTED Blueprint Medicines BPMC	356	+3	+0.8%	$8.65B
22	22 Recursion Pharmaceuticals RXRX $2.28B	332	-4	-1%	$1.57B
23	23 Qiagen QGEN $9.59B	319	+19	+6%	$7.23B
24	24 Takeda Pharmaceutical TAK $63.1B	317	+7	+2%	$1.2B
25	25 Revolution Medicines RVMD $41B	308	+24	+8%	$7.02B